Tigecycline
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Mycobacterium Abscessus Lung Disease
Conditions
Mycobacterium Abscessus Lung Disease, Rapidly Growing Mycobacterial Lung Disease
Trial Timeline
Apr 1, 2002 → Dec 1, 2010
NCT ID
NCT00600600About Tigecycline
Tigecycline is a phase 2 stage product being developed by Pfizer for Mycobacterium Abscessus Lung Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT00600600. Target conditions include Mycobacterium Abscessus Lung Disease, Rapidly Growing Mycobacterial Lung Disease.
What happened to similar drugs?
3 of 8 similar drugs in Mycobacterium Abscessus Lung Disease were approved
Approved (3) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (18)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01560143 | Approved | Completed |
| NCT01401023 | Pre-clinical | Completed |
| NCT01072539 | Pre-clinical | Completed |
| NCT00827541 | Pre-clinical | Completed |
| NCT00575094 | Phase 3 | Completed |
| NCT00419991 | Approved | Completed |
| NCT00406237 | Phase 1 | Completed |
| NCT00488488 | Pre-clinical | Completed |
| NCT00376324 | Phase 1 | Completed |
| NCT00488306 | Approved | Completed |
| NCT00488761 | Approved | Completed |
| NCT00136201 | Phase 3 | Completed |
| NCT00205816 | Phase 3 | Completed |
| NCT00079989 | Phase 3 | Completed |
| NCT00079885 | Phase 3 | Completed |
| NCT00079976 | Phase 3 | Completed |
| NCT00081744 | Phase 3 | Completed |
| NCT00600600 | Phase 2 | Completed |
Competing Products
20 competing products in Mycobacterium Abscessus Lung Disease